The MAPRx comments address four areas: (1) formulary access and utilization management protections for selected drugs; (2) the codified patient engagement process; (3) transparency requirements for the Maximum Fair Price (MFP) explanation; and (4) treatment of new fixed combination drugs with a new route of administration. Read more
